09. 11(Thu)
09. 11(Thu) 13:00~14:30 Room 1
TBD
09. 11(Thu) 13:00~14:30 Room 2
Cutting-edge Nutritional Approach for Cardiometaboic Risk Strategies
09. 11(Thu) 13:00~14:30 Room 3
TBD
09. 11(Thu) 13:00~14:30 Room 4
Lipid Metabolism at the Crossroads of Inflammation, Toxicity, and Atherosclerosis
- From nanoparticles to biocides: how toxic chemicals alter lipid homeostasis and accelerate atherosclerotic events 13:00~13:20
- Immune modulation of lipid metabolism promotes BAT whitening under thermoneutral conditions 13:20~13:40
- Lipidomics based understanding of human disease 13:40~14:00
- Panel Discussion 14:00~14:30
09. 11(Thu) 14:40~16:10 Room 2
TBD
09. 11(Thu) 14:40~16:10 Room 3
CVD Risk Prediction in Special Population
09. 11(Thu) 14:40~16:10 Room 4
Redefining Cardiovascular Care: PCSK9 Mechanisms and siRNA-based Advances
09. 11(Thu) 16:20~17:50 Room 1
Recent Prognostic Evidence for the Triglyceride-Glucose (TyG) Index as a Novel Surrogate Marker of Insulin Resistance
09. 11(Thu) 16:20~17:50 Room 3
How Low is Low Enough for LDL-C in Diabetes?
09. 11(Thu) 16:20~17:50 Room 4
Socioeconomic Status: The Missing Piece in Cardiovascular Risk Stratification
09. 12(Fri)
09. 12(Fri) 08:30~10:00 Room 1
Genetic Insights into Dyslipidemia and Diabetes: Pathways, Predictions, and Interventions
- Exloring the genetic landscape of CVD and dyslipidemia: finding and future implication 08:30~08:50
- Prioritization of therapeutic targets for dyslipidemia using integrative multi-omics and multi-trait analysis 08:50~09:10
- Recent progress in gene therapy for familial hypercholesterolemia treatment 09:10~09:30
- Panel Discussion 09:30~10:00
09. 12(Fri) 08:30~10:00 Room 3
Residual CV Risk Era: Remnant Cholesterol
- Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy 08:30~08:50
- Association between remnant cholesterol and sarcopenia: implications on muscle health 08:50~09:10
- Targeting remnant cholesterol in the era of precision lipid management 09:10~09:30
- Panel Discussion 09:30~10:00
09. 12(Fri) 08:30~10:00 Room 4
Shaping the Future of Lipid Management: Insights from the New Consensus and Current Dyslipidemia Trends
09. 12(Fri) 13:00~14:30 Room 2
What is Important beyond Stenosis in Intracranial Atherosclerosis
09. 12(Fri) 13:00~14:30 Room 3
Nontraditional Risk Factors for ASCVD
- Environmental pollution as a nontraditional risk factor for atherosclerotic cardiovascular disease: mechanisms and impacts 13:00~13:20
- Health inequity and its role as a nontraditional risk factor in the prevalence and severity of ASCVD 13:20~13:40
- Sleep disorders: an overlooked nontraditional risk factor in atherosclerotic cardiovascular disease development 13:40~14:00
- Panel Discussion 14:00~14:30
09. 12(Fri) 13:00~14:30 Room 4
Defining the Optimal LDL-C Target for Prevention of Atherosclerotic Cardiovascular and Cerebrovascular Disease
- Optimal LDL-C goals for secondary prevention in high-risk patients - a cardiologist’s perspective 13:00~13:20
- Optimal LDL-C level for stroke prevention - insights from a neurologist’s perspective 13:20~13:40
- Different LDL-C targets by duration of diabetes: what is the evidence? - an endocrinologist’s perspective 13:40~14:00
- Panel Discussion 14:00~14:30
09. 12(Fri) 16:45~18:15 Room 1
Emerging Drugs for Dyslipidemia Management
09. 12(Fri) 16:45~18:15 Room 3
Sex and Gender Differences in Cardiometabolic Health: From Biology to Treatment
09. 12(Fri) 16:45~18:15 Room 4
Immunometabolic Programming of Macrophages in Cardiovascular Injury and Repair
09. 13(Sat)
09. 13(Sat) 08:50~10:10 Room 3
Optimized Management of Cardiometabolic Syndrome in the Elderly: Focus on Multimorbidity and Frailty
- Strategies for managing hyperlipidemia in fragile elderly patients 08:50~09:10
- Optimizing glucose control in fragile elderly patients with cardiometabolic syndrome 09:10~09:30
- How to deal with multimorbidity and frailty for the prevention of cardiovascular disease 09:30~09:50
- Panel Discussion 09:50~10:20
09. 13(Sat) 08:50~10:20 Room 4
From Treatment to Prevention: A Paradigm Shift in Obesity
09. 13(Sat) 14:50~16:20 Room 1
09. 13(Sat) 14:50~16:20 Room 3
Atherosclerosis Beyond Traditional Risks: Emerging Clinical Challenges in Comorbid Conditions
- Atherosclerosis and lipid management in cancer survivors: balancing cardiovascular and oncologic risks 14:50~15:10
- Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk equivalent 15:10~15:30
- Atherosclerosis in chronic inflammatory diseases: focus on rheumatoid arthritis and systemic autoimmunity 15:30~15:50
- Panel Discussion 15:50~16:20
09. 13(Sat) 14:50~16:20 Room 4
TBD
09. 13(Sat) 16:20~17:50 Room 1
Dyslipidemia Management in Special Populations
09. 13(Sat) 16:20~17:50 Room 3
Emerging Therapeutics Targeting Myocardial-vascular Interaction in Atherosclerotic Disease
- IKKε-deficient macrophages impede cardiac repair after myocardial infarction by enhancing the macrophage-myofibroblast transition 16:20~16:40
- Sensing ceramides by CYSLTR2 and P2RY6 to aggravate atherosclerosis 16:40~17:00
- Roles of MCU in human platelets on platelet aggregation 17:00~17:20
- Panel Discussion 17:20~17:50
